Parkkila S, Waheed A, Britton R S, Bacon B R, Zhou X Y, Tomatsu S, Fleming R E, Sly W S
The Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, MO 63104, USA.
Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13198-202. doi: 10.1073/pnas.94.24.13198.
Hereditary hemochromatosis (HH) is a common autosomal recessive disease associated with loss of regulation of dietary iron absorption and excessive iron deposition in major organs of the body. Recently, a candidate gene for HH (also called HFE) was identified that encodes a novel MHC class I-like protein. Most patients with HH are homozygous for the same mutation in the HFE gene, resulting in a C282Y change in the HFE protein. Studies in cultured cells show that the C282Y mutation abrogates the binding of the recombinant HFE protein to beta2-microglobulin (beta2M) and disrupts its transport to the cell surface. The HFE protein was shown by immunohistochemistry to be expressed in certain epithelial cells throughout the human alimentary tract and to have a unique localization in the cryptal cells of small intestine, where signals to regulate iron absorption are received from the body. In the studies presented here, we demonstrate by immunohistochemistry that the HFE protein is expressed in human placenta in the apical plasma membrane of the syncytiotrophoblasts, where the transferrin-bound iron is normally transported to the fetus via receptor-mediated endocytosis. Western blot analyses show that the HFE protein is associated with beta2M in placental membranes. Unexpectedly, the transferrin receptor was also found to be associated with the HFE protein/beta2M complex. These studies place the normal HFE protein at the site of contact with the maternal circulation where its association with transferrin receptor raises the possibility that the HFE protein plays some role in determining maternal/fetal iron homeostasis. These findings also raise the question of whether mutations in the HFE gene can disrupt this association and thereby contribute to some forms of neonatal iron overload.
遗传性血色素沉着症(HH)是一种常见的常染色体隐性疾病,与饮食中铁吸收调节功能丧失以及铁在人体主要器官中过度沉积有关。最近,已鉴定出HH的一个候选基因(也称为HFE),它编码一种新的MHC I类样蛋白。大多数HH患者在HFE基因中具有相同突变的纯合子,导致HFE蛋白发生C282Y变化。在培养细胞中的研究表明,C282Y突变消除了重组HFE蛋白与β2-微球蛋白(β2M)的结合,并破坏了其向细胞表面的转运。免疫组织化学显示,HFE蛋白在整个人体消化道的某些上皮细胞中表达,并在小肠隐窝细胞中具有独特的定位,在那里接收来自身体的调节铁吸收的信号。在本文所呈现的研究中,我们通过免疫组织化学证明,HFE蛋白在人胎盘中的合体滋养层顶端质膜中表达,在这里,与转铁蛋白结合的铁通常通过受体介导的内吞作用转运给胎儿。蛋白质印迹分析表明,HFE蛋白与胎盘膜中的β2M相关。出乎意料的是,还发现转铁蛋白受体与HFE蛋白/β2M复合物相关。这些研究将正常的HFE蛋白置于与母体循环接触的部位,其与转铁蛋白受体的关联增加了HFE蛋白在确定母体/胎儿铁稳态中发挥某种作用的可能性。这些发现还提出了一个问题,即HFE基因中的突变是否会破坏这种关联,从而导致某些形式的新生儿铁过载。